hCD3EDG/hCD19/hBCMA

Fig.1 Expression analysis of hBCMA in spleen of hCD3EDG/hCD19/hBCMA humanized mice. 

Leukocytes were collected from homozygous hCD3EDG/hCD19/hBCMA mice that had been treated with or without GSI (γ-secretase inhibitor) in vivo, and analyzed by flow cytometry with anti-hBCMA. hBCMA was exclusively detectable in hBCMA humanized mice but not in wild-type mice.

Fig.2 Expression analysis of hBCMA in spleen of hCD3EDG/hCD19/hBCMA humanized mice. 

Leukocytes were collected from homozygous hCD3EDG/hCD19/hBCMA mice, treated with or without 1 μM GSI (γ-secretase inhibitor) in vitro, and analyzed by flow cytometry with anti-hBCMA. hBCMA was exclusively detectable in hBCMA humanized mice but not in wild-type mice.

Fig.3 Detection of immune cell subpopulations in the blood of 7-8-week-old female mice by FACS (n=3 in all groups). 

Abbr.  WT, wild type; HO, homozygous.

Fig.4 Detection of immune cell subpopulations in the blood of 7-8-week-old male mice by FACS (n=3 in all groups).  

Abbr.  WT, wild type; HO, homozygous.

Fig.5 Detection of immune cell subpopulations in the spleen of 7-8-week-old female mice by FACS (n=3 in all groups). 

Abbr.  WT, wild type; HO, homozygous.

Fig.6 Detection of immune cell subpopulations in the spleen of 7-8-week-old male mice by FACS (n=3 in all groups). 

Abbr.  WT, wild type; HO, homozygous.

Fig.7 Detection of immune cell subpopulations in the lymph nodes of 7-8-week-old female mice by FACS (n=2 or 3). 

Abbr.  WT, wild type; HO, homozygous.

Fig.8 Detection of immune cell subpopulations in the lymph nodes of 7-8-week-old male mice by FACS (n=3 in all groups). 

Abbr.  WT, wild type; HO, homozygous.

Table 1. Blood routine examination of hBCMA/hCD3EDG/hCD19 knockin mice. The baseline physiological parameters of hCD3EDG/hCD19/hBCMA mice showed no significant abnormalities.

Abbr. HO, homozygous; WT, wild type. Values are expressed as mean±SEM. 

Table 2. Biochemical test of serum from hBCMA/hCD3EDG/hCD19 knockin mice. 

Abbr. HO, homozygous; WT, wild type. Values are expressed as mean±SEM.

Fig.9 In vivo efficacy study of teclistamab in HO hCD3EDG/hCD19/hBCMA mice. Teclistamab were injected at day 0, 3, 5,  and immune cells in the spleen and bone marrow of mice after therapy were measured by flow cytometry (n=4). 

Teclistamab treatment resulted in a significant reduction of plasma cells in both the spleen and bone marrow of hCD3EDG/hCD19/hBCMA mice. Average±SEM.